Sven Kili, MD, Antion Biosciences SA, Geneva, Switzerland, talks on the current challenges related to the development of cell therapies for solid tumors. He underlines the combined efforts from industry and academia to improve access to the tumor microenvironment, control different cell types and gain better access into the tumor without causing harm to patients. A wide range of strategies are currently being investigated to address these obstacles which include the use of different vectors and cell types, as well as adjuvant approaches. This interview took place at the Advanced Therapies Congress & Expo 2021.